SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Science Exchange, the leading marketplace for outsourced R&D, and Certis Oncology, a leading provider for preclinical mouse modeling and tumor banking services, announced they are working together to bring Certis’ breakthrough orthotopic PDX-based CRO services to the global research community of Science Exchange.
Certis’ Orthotopic Patient-Derived Xenografts (PDXs) provides a cost-effective model for developing new drugs to battle all types of cancers. Using the orthotopic technique, Certis scientists take a very small specimen of the human patient’s tumor and surgically implant it into the corresponding anatomic location (pancreas, liver, lung, etc.) in immunodeficient mice. Pharmaceutical and biotech companies contract with Certis to develop custom mouse models to test against all types of solid tumors to determine the effectiveness of new drugs they are developing.
“Our primary objective is to save and extend lives,” said Peter Ellman, CEO at Certis Oncology. “To help us achieve this goal, Science Exchange is providing us with the reach and support to expedite the availability of our pre-clinical and tumor banking services to companies around the world that are developing new cancer drugs.”
“Certis’s Orthotopic PDX technique has proven to rapidly grow individual patient tumors in mice at a high rate,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “The orthotopic models more accurately replicate human tumor growth, metastasis and response to therapy, making it more immediately clinically relevant than other models. Success with drug testing on these mice can help determine which drugs are suitable for human clinical trials.”
About Science Exchange
Science Exchange is the world's leading marketplace for outsourced R&D, providing large R&D organizations with the fastest path from discovery through development and commercialization. Science Exchange includes an efficient source-to-secure platform for ordering 6,000+ services from a network of more than 2,500 qualified outsourced research providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange, Facebook, and LinkedIn.
About Certis Oncology
Certis Oncology Solutions was formed in 2016 with the mission to provide individualized precision patient care. Certis’ oncologist-directed therapy enables oncologists to tailor and optimize therapies for patients suffering from aggressive cancers. Certis also provides pre-clinical services for pharmaceutical and biotech companies. In more than 40 published peer-reviewed studies, we have demonstrated the ability of our Orthotopic PDX tumors to grow in immunodeficient mice at a high rate and replicate patient outcomes. Certis is affiliated with leading cancer physicians from UCLA and Memorial Sloan Kettering. Follow Certis on @CertisOncology, LinkedIn and YouTube.
Contacts
Science Exchange
Gursatya "Guru" Singh
Director of Scientific Content
marketing@scienceexchange.com
Certis Oncology
Evan Birkhead
Marketing
info@certisoncology.com